Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study

Table 2 Clinical features of venous thromboembolism in advanced gastric cancer patients receiving chemotherapy n (%)

	Total (n = 27)	Symptomatic VTE (n = 13)	Incidental VTE (n = 14)	P value
Time to VTE duration (median, mo)	6.1	7.5	4.7	0.16
VTE incidence
< 3	10 (37.0)	4 (30.8)	6 (42.9)
3-6	6 (22.2)	3 (23.1)	3 (21.5)
6-12	7 (25.9)	3 (23.1)	4 (28.6)
> 12	4 (14.8)	3 (23.1)	1 (7.2)	0.68
Types of VTE
DVT	19 (70.4)	8 (61.5)	11 (78.6)
PTE	4 (14.8)	3 (23.1)	1 (7.2)
PTE + DVT	4 (14.8)	2 (15.4)	2 (14.3)	0.608
Treatment of VTE
Medication (anticoagulation)	22 (81.4)	10 (76.9)	12 (75.7)
IVC filter	3 (11.1)	3 (23.1)	0
No treatment	2 (7.5)	0	2 (14.3)	0.031
Delay of chemotherapy
None	17 (62.9)	5 (38.5)	12 (85.7)
Yes	10 (37.1)	8 (61.5)	2 (14.3)	0.018

DVT: Deep vein thrombosis; PTE: Pulmonary thrombosis; VTE: Venous thromboembolism; IVC: Inferior venous cava.